Skye Bioscience, Inc. Common Stock Total Liabilities
Skye Bioscience, Inc. Common Stock total liabilities. Based on the latest financial reports, Skye Bioscience, Inc. Common Stock (SKYE) has total liabilities worth $11.53 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Skye Bioscience, Inc. Common Stock asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Skye Bioscience, Inc. Common Stock (2012–2025)
Total liabilities of Skye Bioscience, Inc. Common Stock from 2012 to 2025. This chart illustrates how Skye Bioscience, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Skye Bioscience, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Skye Bioscience, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Prolexus Bhd
KLSE:8966
|
Malaysia | RM66.41 Million |
|
CN Asia Corporation Bhd
KLSE:7986
|
Malaysia | RM17.69 Million |
|
DB ENERGY S.A. ZY -10
F:0CJ
|
Germany | €36.93 Million |
|
Robogroup
TA:ROBO
|
Israel | ILA12.54 Million |
|
Proodeftiki S.A.
AT:PRD
|
Greece | €9.29 Million |
|
5E ADVANCED MATERIALS CDI
F:J9I0
|
Germany | €6.99 Million |
|
Ferguson Plc
LSE:FERG
|
UK | GBX11.91 Billion |
|
Palamina Corp
V:PA
|
Canada | CA$695.24K |
Liability Composition Analysis (2012–2025)
This chart breaks down Skye Bioscience, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Skye Bioscience, Inc. Common Stock (SKYE) total assets.
Liquidity & Leverage Metrics
Skye Bioscience, Inc. Common Stock Total Liabilities Ratios Explained
Skye Bioscience, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -23.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Skye Bioscience, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Skye Bioscience, Inc. Common Stock (2012–2025)
The table below shows the annual total liabilities of Skye Bioscience, Inc. Common Stock from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.29 Million | +79.73% |
| 2024-12-31 | $4.61 Million | -67.23% |
| 2023-12-31 | $14.07 Million | +16.12% |
| 2022-12-31 | $12.12 Million | +203.67% |
| 2021-12-31 | $3.99 Million | +79.70% |
| 2020-12-31 | $2.22 Million | +53.31% |
| 2019-12-31 | $1.45 Million | -91.73% |
| 2018-12-31 | $17.52 Million | +1190.76% |
| 2017-12-31 | $1.36 Million | -23.50% |
| 2016-12-31 | $1.77 Million | -41.64% |
| 2015-12-31 | $3.04 Million | +279.11% |
| 2014-12-31 | $801.89K | +340.23% |
| 2013-12-31 | $182.15K | +4111.63% |
| 2012-12-31 | $4.33K | -- |
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1… Read more